REVENUE AND DEFERRED INCOME (Tables)

12 Months Ended

Jun. 30, 2024

Notes and other explanatory information [abstract]

SUMMARY OF REVENUE

	2024 A$		2023 A$		2022 A$
Sales of EasyDNA branded test - point in time		6,162,865		7,698,605		5,989,782
Sales of AffinityDNA branded test - point in time		1,367,834		944,058		-
Sales of geneType branded test - point in time		134,085		43,455		7,551
License fees - over time		-		-		797,483
Total revenue from contract with customers		7,664,784		8,686,118		6,794,816

SCHEDULE OF DISAGGREGATED BY GEOGRAPHICAL MARKETS

The Group’s revenue disaggregated by primary geographical markets is as follows:

	2024 A$		2023 A$		2022 A$
America and Canada		1,666,961		2,242,169		2,274,551
Europe Middle East and Africa		4,069,799		4,494,626		2,501,302
Latin America		190,422		322,033		128,840
Asia Pacific		1,737,602		1,627,290		1,890,123
Total revenue		7,664,784		8,686,118		6,794,816

SCHEDULE OF CONTRACT BALANCES

	Note		2024 A$		2023 A$
Receivables, which are included in ‘net trade receivables’		12		209,254		1,049,393
Contract liabilities				741,647		849,212